Covid-19 Vaccine, mRNA
- TRADE NAMES: BNT162b2 (Pfizer-BioNTech); Comirnaty (Pfizer-BioNTech); Comirnaty (Pfizer-BioNTech); Tozinameran (Pfizer-BioNTech)
- INDICATIONS: Prevention of coronavirus disease 2019 (Covid-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- SYNONYM: Pfizer-BioNTech Covid-19 mRNA Vaccine
- CLASS: Covid-19 vaccine, Vaccine
FDA APPROVAL DATE: 08/23/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
Insufficient data to inform of vaccine-associated risks in pregnancy.
Increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The observed risk is higher among males under 40 years of age than among females and older males. The observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae. The Centers for Disease Control and Prevention (CDC) have published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis.
Please login to see the rest of this drug profile
Page last updated 03/05/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric